Literature DB >> 31498410

Trajectories of Cognitive Function Prior to Cancer Diagnosis: A Population-Based Study.

Kimberly D van der Willik1,2, Michael Hauptmann3, Katarzyna Jóźwiak3, Elisabeth J Vinke2, Rikje Ruiter2, Bruno H Stricker2, Annette Compter4, M Arfan Ikram2, Sanne B Schagen5.   

Abstract

BACKGROUND: An emerging body of research suggests that noncentral nervous system cancer may negatively impact the brain apart from effects of cancer treatment. However, studies assessing cognitive function in newly diagnosed cancer patients cannot exclude selection bias and psychological effects of cancer diagnosis. To overcome these limitations, we investigated trajectories of cognitive function of patients before cancer diagnosis.
METHODS: Between 1989 and 2013, a total of 2059 participants from the population-based Rotterdam Study were diagnosed with noncentral nervous system cancer. Cognitive assessments were performed every 3 to 5 years using a neuropsychological battery. The general cognitive factor was composed of individual cognitive tests to assess global cognition. Using linear mixed models, we compared change in cognitive function of cancer case patients before diagnosis with cognitive change of age-matched cancer-free control subjects (1:2). In addition, we performed sensitivity analyses by discarding assessments of control subjects 5 years before the end of follow-up to exclude effects from potential undiagnosed cancer. All statistical tests were two-sided.
RESULTS: The Word Learning Test immediate recall declined faster among case patients than among control subjects (-0.05, 95% confidence interval = -0.09 to -0.01 vs 0.01, 95% confidence interval = -0.01 to 0.03; P for difference = .003). However, this difference was not statistically significant in sensitivity analyses. Furthermore, no statistically significant differences were observed in change of other individual cognitive tests and of the general cognitive factor.
CONCLUSIONS: In this study, we evaluated cognitive function in a large group of cancer patients prior to diagnosis, thereby excluding the psychological impact of cancer diagnosis and biased patient selection. In contrast to previous studies shortly after cancer diagnosis, we found no difference in change of cognitive function between cancer patients and control subjects.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2020        PMID: 31498410      PMCID: PMC7225679          DOI: 10.1093/jnci/djz178

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  38 in total

Review 1.  Chemotherapy-related cognitive dysfunction.

Authors:  Jeffrey S Wefel; Sanne B Schagen
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

2.  Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies.

Authors:  Kaarin J Anstey; Chwee von Sanden; Agus Salim; Richard O'Kearney
Journal:  Am J Epidemiol       Date:  2007-06-14       Impact factor: 4.897

Review 3.  Prevalence, mechanisms, and management of cancer-related cognitive impairment.

Authors:  Michelle C Janelsins; Shelli R Kesler; Tim A Ahles; Gary R Morrow
Journal:  Int Rev Psychiatry       Date:  2014-02

4.  Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort.

Authors:  Lori J Bernstein; Gregory R Pond; Hui K Gan; Kattleya Tirona; Kelvin K Chan; Andrew Hope; John Kim; Eric X Chen; Lillian L Siu; Albiruni R Abdul Razak
Journal:  Head Neck       Date:  2018-04-17       Impact factor: 3.147

5.  Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study.

Authors:  Kerstin Hermelink; Michael Untch; Michael P Lux; Rolf Kreienberg; Thomas Beck; Ingo Bauerfeind; Karin Münzel
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

6.  Alcohol consumption and risk of dementia: the Rotterdam Study.

Authors:  Annemieke Ruitenberg; John C van Swieten; Jacqueline C M Witteman; Kala M Mehta; Cornelia M van Duijn; Albert Hofman; Monique M B Breteler
Journal:  Lancet       Date:  2002-01-26       Impact factor: 79.321

7.  Neurobiological Mechanisms of Chemotherapy-induced Cognitive Impairment in a Transgenic Model of Breast Cancer.

Authors:  Gordon Winocur; Hal Berman; Mary Nguyen; Malcolm A Binns; Mark Henkelman; Matthijs van Eede; Micheline Piquette-Miller; Melanie J Sekeres; J Martin Wojtowicz; Johnson Yu; Haibo Zhang; Ian F Tannock
Journal:  Neuroscience       Date:  2017-11-04       Impact factor: 3.590

8.  Education and rates of cognitive decline in incident Alzheimer's disease.

Authors:  N Scarmeas; S M Albert; J J Manly; Y Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

9.  Age-related sex differences in verbal memory.

Authors:  M L Bleecker; K Bolla-Wilson; J Agnew; D A Meyers
Journal:  J Clin Psychol       Date:  1988-05

10.  The Impact of Using Different Reference Populations on Measurement of Breast Cancer-Related Cognitive Impairment Rates.

Authors:  Jonathan D Clapp; George Luta; Brent J Small; Tim A Ahles; James C Root; Deena Graham; Arti Hurria; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Robert A Stern; Andrew J Saykin; Jeanne S Mandelblatt
Journal:  Arch Clin Neuropsychol       Date:  2018-12-01       Impact factor: 2.813

View more
  6 in total

1.  Understanding the Time Course of Cancer-Associated Cognitive Decline: Does Impairment Precede Diagnosis?

Authors:  Brent J Small; Heather S L Jim
Journal:  J Natl Cancer Inst       Date:  2020-05-01       Impact factor: 13.506

Review 2.  Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?

Authors:  Sanne B Schagen; Andrey S Tsvetkov; Annette Compter; Jeffrey S Wefel
Journal:  Nat Rev Neurol       Date:  2022-02-09       Impact factor: 44.711

3.  Understanding Longitudinal Changes in Cognitive Function in Lymphoma Patients: Where to Next?

Authors:  Janette L Vardy; Joanna Fardell
Journal:  J Natl Cancer Inst       Date:  2022-01-11       Impact factor: 11.816

4.  Objectives, design and main findings until 2020 from the Rotterdam Study.

Authors:  M Arfan Ikram; Guy Brusselle; Mohsen Ghanbari; André Goedegebure; M Kamran Ikram; Maryam Kavousi; Brenda C T Kieboom; Caroline C W Klaver; Robert J de Knegt; Annemarie I Luik; Tamar E C Nijsten; Robin P Peeters; Frank J A van Rooij; Bruno H Stricker; André G Uitterlinden; Meike W Vernooij; Trudy Voortman
Journal:  Eur J Epidemiol       Date:  2020-05-04       Impact factor: 8.082

5.  Brain structure prior to non-central nervous system cancer diagnosis: A population-based cohort study.

Authors:  Kimberly D van der Willik; Pinar Yilmaz; Annette Compter; Michael Hauptmann; Katarzyna Jóźwiak; Rikje Ruiter; Bruno H Ch Stricker; Meike W Vernooij; M Arfan Ikram; Michiel B de Ruiter; Sanne B Schagen
Journal:  Neuroimage Clin       Date:  2020-10-13       Impact factor: 4.881

6.  Protective Effects of APOE ε2 Genotype on Cognition in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study.

Authors:  Kathleen Van Dyk; Xingtao Zhou; Brent J Small; Jaeil Ahn; Wanting Zhai; Tim Ahles; Deena Graham; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Kelly Nudelman Holohan; Sunita K Patel; G William Rebeck; James C Root; Andrew J Saykin; Harvey Jay Cohen; Jeanne S Mandelblatt; Judith E Carroll
Journal:  JNCI Cancer Spectr       Date:  2021-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.